Skip to main content
. 2014 May 14;27(2):100–112. doi: 10.2337/diaspect.27.2.100

Figure 2.

Figure 2.

Pathophysiological abnormalities targeted by currently available antidiabetic medications. DPP4i, dipeptidyl peptidase-4 inhibitor; GLP1 RA, glucagon-like peptide-1 receptor agonist; HGP, hepatic glucose production; MET, metformin; SGLT2i, sodium glucose co-transporter 2 inhibitor; TZD, thiazolidinedione.